Rep. Lisa C. McClain Buys Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Representative Lisa C. McClain (R-Michigan) recently bought shares of Roivant Sciences Ltd. (NASDAQ:ROIV). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in Roivant Sciences stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Roivant Sciences Stock Down 0.3%

ROIV traded down $0.06 during trading on Friday, hitting $20.82. The company had a trading volume of 2,345,700 shares, compared to its average volume of 6,505,934. The company has a market capitalization of $14.48 billion, a PE ratio of -37.17 and a beta of 1.23. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $21.35. The firm’s 50-day moving average price is $18.15 and its 200 day moving average price is $13.91.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Roivant Sciences by 10.0% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 102,478 shares of the company’s stock valued at $1,034,000 after purchasing an additional 9,357 shares during the last quarter. Corton Capital Inc. acquired a new stake in Roivant Sciences in the first quarter valued at about $111,000. XTX Topco Ltd grew its position in Roivant Sciences by 634.1% in the first quarter. XTX Topco Ltd now owns 256,714 shares of the company’s stock valued at $2,590,000 after acquiring an additional 221,742 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Roivant Sciences by 44.8% during the first quarter. PNC Financial Services Group Inc. now owns 10,248 shares of the company’s stock worth $103,000 after acquiring an additional 3,169 shares in the last quarter. Finally, New Age Alpha Advisors LLC lifted its holdings in shares of Roivant Sciences by 37.1% in the first quarter. New Age Alpha Advisors LLC now owns 21,966 shares of the company’s stock worth $222,000 after acquiring an additional 5,943 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. The Goldman Sachs Group increased their price target on Roivant Sciences from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. Bank of America raised their target price on shares of Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research note on Thursday, September 18th. Weiss Ratings raised shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. Leerink Partners reissued an “outperform” rating and issued a $29.00 price objective on shares of Roivant Sciences in a research report on Tuesday, November 11th. Finally, HC Wainwright boosted their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.56.

Insider Activity

In related news, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $20.22, for a total value of $4,044,000.00. Following the completion of the transaction, the chief executive officer owned 1,504,959 shares of the company’s stock, valued at $30,430,270.98. This represents a 11.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Allen Gold sold 1,300,000 shares of the firm’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00. Following the sale, the director directly owned 18,047,727 shares in the company, valued at approximately $365,105,517.21. This trade represents a 6.72% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 8,483,561 shares of company stock worth $143,557,750. Corporate insiders own 10.80% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.